Hepatitis B Surface Antigen Recombinant Vaccine
Recommended VaccinesRestrictedNot applicable line
Active immunisation against hepatitis B virus infection in adolescents and adults, listed temporarily on the NIP due to shortage of H-B-Vax II adult formulation.
1
Submissions
2018–18
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Jul 2018 Recommended Hepatitis B virus infection
Access path
- Jul 2018Recommended · restricted
vs H-B-Vax II
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
5.1 The PBAC recommended the temporary listing of Engerix-B (adult formulation) for use in adolescents and adults on the NIP until either the shortage of H-B-Vax II (adult formulation) has been resolved, or 31 December 2019, whichever were to occur first.PSD · Jul 2018
Cost-effectiveness
Cost-neutral basis; no ICER calculated as this is a temporary supply shortage response with equivalent clinical protection to comparator.
Cost-effectiveness accepted
Decision context
PopulationAdolescents aged 10-19 years old and refugees and humanitarian entrants of all ages requiring hepatitis B vaccination.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2018 | Recommended · restricted | H-B-Vax II | — | Cost-minimisation · Cost-minimisation |
Similar precedents
Meningococcal Group B Vaccine, Multicomponent (4cmenb)69%Dtpa-Hepb-Ipv-Hib Vaccine68%Human Rotavirus Vaccine68%Meningococcal Group B Vaccine (4cmenb)67%Meningococcal Group B Vaccine (Recombinant, Adsorbed)67%Varicella Zoster Virus Recombinant Vaccine66%Entecavir65%Human Papillomavirus (Hpv) Types 16/18 Vaccine65%